Suppr超能文献

异源 Ad26/Ad5 腺病毒载体疫苗诱导产生了具有强大 Fc 活性的 SARS-CoV-2 特异性抗体反应。

Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.

机构信息

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

James J. Peters VA Medical Center, Bronx, NY, United States.

出版信息

Front Immunol. 2024 May 8;15:1382619. doi: 10.3389/fimmu.2024.1382619. eCollection 2024.

Abstract

INTRODUCTION

Antibodies against the SARS-CoV-2 spike protein are a critical immune determinant for protection against the virus. While virus neutralization is a key function of spike-specific antibodies, antibodies also mediate Fc-dependent activities that can play a role in protection or pathogenesis.

METHODS

This study characterized serum antibody responses elicited after two doses of heterologous adenovirus-vectored (Ad26/ Ad5) vaccines.

RESULTS

Vaccine-induced antibody binding titers and Fc-mediated functions decreased over six months, while neutralization titers remained stable. Comparison of antibody isotypes elicited after Ad26/Ad5 vs. LNP-mRNA vaccination and after infection showed that anti-spike IgG1 were dominant and produced to high levels in all groups. The Ad26/Ad5 vaccines also induced IgG4 but not IgG2 and IgG3, whereas the LNP-mRNA vaccines elicited a full Ig spectrum (IgM, IgG1-4, IgA1-2). Convalescent COVID-19 patients had mainly IgM and IgA1 alongside IgG1. Despite these differences, the neutralization potencies against early variants were similar. However, both vaccine groups had antibodies with greater Fc potencies of binding complement and Fcg receptors than the COVID-19 group. The Ad26/Ad5 group also displayed a greater potency of RBD-specific antibody-mediated cellular phagocytosis.

DISCUSSION

Antibodies with distinctive quality were induced by different vaccines and infection. The data imply the utility of different vaccine platforms to elicit antibody responses with fine-tuned Fc activities.

摘要

简介

针对 SARS-CoV-2 刺突蛋白的抗体是针对该病毒的保护性免疫决定因素。虽然病毒中和是刺突特异性抗体的关键功能,但抗体也介导 Fc 依赖性活性,这些活性可能在保护或发病机制中发挥作用。

方法

本研究对两剂异源腺病毒载体(Ad26/Ad5)疫苗引起的血清抗体反应进行了描述。

结果

疫苗诱导的抗体结合滴度和 Fc 介导的功能在六个月内下降,而中和滴度保持稳定。Ad26/Ad5 与 LNP-mRNA 疫苗接种后和感染后诱导的抗体同种型的比较表明,抗刺突 IgG1 是优势抗体,在所有组中均产生高水平。Ad26/Ad5 疫苗还诱导 IgG4,但不诱导 IgG2 和 IgG3,而 LNP-mRNA 疫苗则诱导完整的 Ig 谱(IgM、IgG1-4、IgA1-2)。恢复期 COVID-19 患者主要产生 IgM 和 IgA1 以及 IgG1。尽管存在这些差异,但针对早期变异体的中和效力相似。然而,与 COVID-19 组相比,两组疫苗接种者的抗体均具有更高的结合补体和 Fcg 受体的 Fc 效力。Ad26/Ad5 组还显示出针对 RBD 特异性抗体介导的细胞吞噬作用的更高效力。

讨论

不同的疫苗和感染诱导了具有独特质量的抗体。这些数据表明,不同的疫苗平台可用于诱导具有精细 Fc 活性的抗体反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/67c6d2c341da/fimmu-15-1382619-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验